News updates

Nosebleeds associated with amlodipine use

Netherlands Pharmacovigilance Centre Lareb received 8 reports of nosebleeds associated with the use of amlodipine. In most cases, the nosebleeds star...

Results Lareb Intensive Monitoring NOACs

Adverse drug reactions (ADRs) of non-vitamin K oral anticoagulants (NOACs) mostly occur in the first week of treatment. For over half of these ADRs th...

Potential liver toxicity of herbal supplement NMDA relief Exendo

The Netherlands Pharmacovigilance Centre Lareb received two reports of liver toxicity associated with the use of herbal supple...

First results of Dutch Biologic Monitor

48% of patients experienced at least one adverse drug reaction (ADR) after administration of a biological drug. ADRs most often reported were injection...

Overview reports on Meningococcal group ACWY vaccine (Nimenrix)

Since May 1st, 2018, all children aged 14 months in the Netherlands are vaccinated against Meningococcal type ACWY with the vac...

ConcePTION project has been launched

Today, only about 5% of medications have adequate safety information on use in pregnant or breastfeeding women. Obtaining reliable safety information can ...

Hair loss associated with use tioguanine (Thiosix) for inflammatory bowel disease

Over the last five years, the Netherlands Pharmacovigilance Centre Lareb received twenty reports of hair loss...

More adverse drug reactions are reported for women

Women have a higher risk of adverse drug reactions (ADRs) being reported than men, even when differences in the number of drug users is take...

Fifteen years of patient reporting

Patients’ reports can contribute to signal detection and add value to pharmacovigilance. However, Lareb recognizes that there is a big leap between allowing...